ZB ZBH Zimmer Biomet Loading... : Bullish and Bearish Analyst Opinions

Management is confident, raising both organic growth and adjusted EPS guidance for the full year based on strong first-half performance, successful sales force transformation, and product momentum.

JNJ called out a modest cost-of-goods-sold tailwind from tariffs in medtech (offset other headwinds), implying some near-term tariff recoupment that may be incremental for the sector. — JNJ's ability to partially offset tariff costs through price or mix suggests a more resilient margin structure, contrasting with competitors who may not have similar leverage.

The author provides a detailed cross-asset market summary describing a chip-led tech selloff.

The author expresses a strong bearish opinion on Zimmer Biomet.

Despite beating expectations, management is maintaining a confident but measured tone, noting that the year is a transition period. While they raised EPS and FCF guidance, they left revenue unchanged, preferring to wait 90 days before reassessing.

The tweet shares a link regarding a medical device industry development without providing.

Management's tone is cautious, guiding to low-single-digit growth in 2026, explicitly citing short-term disruption from a massive US sales force restructuring which outweighs a strong Q4 exit rate.

Stryker's record Mako 4 installation quarter and elevated capital order book into 2026 point to continued hospital spending on orthopaedic robotics, putting share pressure on implant rivals with less robot scale. — Another record placement wave plus high Mako utilization implies Stryker's robotic attach continues to take knee/hip share from competitors that lack comparable installed-base momentum.